Endothelin receptor blockers in cardiovascular disease

Area of Science:

• Cardiovascular Pharmacology
• Endocrinology

Background:

• The endothelin (ET) system, particularly ET-1, plays a significant role in cardiovascular function.
• ET-1's potent vasoconstricting and mitogenic effects link it to various cardiovascular diseases.

Purpose of the Study:

• To evaluate the efficacy of ET receptor antagonists in cardiovascular diseases.
• To explore the therapeutic potential of blocking the ET receptor.

Main Methods:

• Review of studies on ET receptor antagonists, including bosentan (nonselective) and sitaxsentan (selective ET A).
• Analysis of clinical outcomes in pulmonary arterial hypertension and congestive heart failure.

Main Results:

• ET receptor antagonism is beneficial in pulmonary hypertension, improving exercise capacity and clinical outcomes.
• Bosentan and sitaxsentan demonstrated positive effects in pulmonary arterial hypertension.
• ET receptor antagonists yielded disappointing results in congestive heart failure, with larger trials being neutral.

Conclusions:

• ET receptor antagonists are effective for pulmonary hypertension.
• Their utility in congestive heart failure is questionable.
• Further investigation into ET receptor antagonists, potentially in combination therapies, is needed for other conditions.